SCH 23390 enhances exogenous L-DOPA decarboxylation in nigrostriatal neurons

Journal of Neural Transmission

Volumn 107, Issue 4, 2000, Pages 429-443

  Neff, N H ^a   Wemlinger, T A ^a   Hadjiconstantinou, M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Aromatic L amino acid decarboxylase; Dopamine; Dopamine D1 receptor antagonists; L DOPA; MPTP; Nigrostriatal neurons; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARBOXYLYASE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DECARBOXYLATION; DENERVATION; DOPAMINE METABOLISM; ENZYME ACTIVITY; MALE; MESENCEPHALON; MOUSE; NERVE CELL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BLOCKING;

EID: 0034076067     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020070085     Document Type: Article

References (61)

1. Abercombie ED, Bonatz AE, Zigmond MJ (1990) Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525: 36-44
2. Altar CA, Boyar WC, Wasley A, Gerhardt SC, Liebman JM, Wood PL (1988) Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naunyn Schmiedebergs Arch Pharmacol 338: 162-168
3. Berry MD, Juorio AV, Li XM, Boulton AA (1996) Aromatic L-amino acid decarboxylase: a neglected and misunderstood enzyme. Neurochem Res 21: 1075-1087
4. Biggs CS, Fisher A, Starr MS (1998) The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra. Synapse 30: 309-317
5. Bischoff S, Heinrich M, Krauss J, Sills MA, Williams M, Vassout A (1988) Interaction of the D1 receptor antagonist SCH 23390 with the central 5-TH system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome. J Recept Res 8: 107-120
6. Brannan T, Knott P, Kaufmann H, Leung L, Yahr M (1989) Intracerebral dialysis monitoring of striatal dopamine release and metabolism in response to L-DOPA. J Neural Transm 75: 149-157
7. Brannan T, Bhardwaj A, Martinez-Tica J, Weinberger J, Yahr M (1990) Striatal L-dopa metabolism studied in vivo in rats with nigrostriatal lesions. J Neural Transm [P-D Sect] 2: 15-22
8. Brannan T, Knott P, Kaufmann H, Yahr M (1990) In vivo studies of striatal dopamine release and metabolism following administration of L-DOPA. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Parkinson's disease: anatomy, pathology, and therapy. Raven Press, New York, pp 75-81 (Adv Neurol 53)
9. Brannan T, Prikojan A, Martinez-Tica J, Yahr MD (1995) In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. J Neural Transm [P-D Sect] 10: 79-89
10. Burkard WP, Gey KF, Pletscher A (1964) Inhibition of decarboxylase of aromatic amino acids by 2,3,4-trihydrobenzylhydrazine and its seryl derivative. Arch Biochem Biophys 107: 187-196
11. Buu NT, Angers M (1987) Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain. Biochem Pharmacol 36: 1731-1735
12. Carlsson A, Lindqvist M (1973) In vivo measurements of tryptophan and tyrosine hydroxylase activities in mouse brain. J Neural Transm 34: 79-91
13. Cho S, Neff NH, Hadjiconstantinou M (1997) Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur J Pharmacol 323: 149-157
14. Cho S, Duchemin A-M, Neff NH, Hadjiconstantinou M (1999) Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs. Brain Res 830: 237-245
15. Commissiong JW, Slimivitch C, Toffano G (1990) Regulation of the synthesis and metabolism of striatal dopamine after disruption of nerve conduction in the medial forebrain bundle. Br J Pharmacol 99: 741-749
16. Cumming P, Ase A, Laliberte C, Kuwabara H, Gjedde A (1997) In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. J Cereb Blood Flow Metab 17: 1254-1260
17. 3H]tyrosine in living rat brain is not committed to dopamine synthesis. J Cereb Blood Flow Metab 18: 491-499
18. Esposito E, Bunney BS (1989) The effect of acute and chronic treatment with SCH 23390 on the spontaneous activity of midbrain dopamine neurons. Eur J Pharmacol 162: 109-113
19. Gjedde A, Leger GC, Cumming P, Yasuhara Y, Evans AC, Guttman M, Kuwabara H (1993) Striatal L-DOPA decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis. J Neurochem 61: 1538-1541
20. Goldstein JM, Litwin LC (1988) Spontaneous activity of A9 and A10 dopamine neurons after acute and chronic administration of the selective dopamine D-1 receptor antagonist SCH 23390. Eur J Pharmacol 155: 175-180
21. Hadjiconstantinou M, Rossetti ZL, Silvia C, Krajnc D, Neff NH (1988) Aromatic L-amino acid decarboxylase activity of the rat retina is modulated in vivo by environmental light. J Neurochem 51: 1560-1564
22. Hadjiconstantinou M, Mariani AP, Neff NH (1989) GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study. Brain Res 484: 297-303
23. Hadjiconstantinou M, Wemlinger TA, Silvia CP, Hubble J, Neff NH (1993) Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopaminergic receptors. J Neurochem 60: 2175-2180
24. Hadjiconstantinou M, Rossetti ZL, Wemlinger TA, Neff NH (1995) Dizocilpine enhances striatal tyrosine hydroxylase and aromatic-L-amino acid decarboxylase activity. Eur J Pharmacol 289: 97-101
25. Hadjiconstantinou M, Neff NH, Zhou LW, Weiss B (1996) D2 dopamine receptor antisense increases the activity and mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in mouse brain. Neurosci Lett 217: 105-108
26. Hefti F, Melamed E, Wurtman RJ (1980) The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model. J Neural Transm [Suppl 16]: 95-101
27. Hefti F, Melamed E, Wurtman RJ (1981) The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther 217: 189-197
28. Hjorth S, Carlssson A (1988) In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH 23390. J Neural Transm 72: 83-97
29. Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopamine systems. J Pharmacol Exp Ther 226: 462-468
30. Kaakkola S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and L-3, 4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60: 137-144
31. Kang UJ, Park DH, Wessel T, Baker H, Joh TH (1992) DOPA-decarboxylation in the striata of rats with unilateral substantia nigra lesions. Neurosci Lett 147: 53-57
32. Kuwabara H, Cumming P, Yasuhara Y, Leger GC, Guttman M, Diksic M, Evans AC, Gjedde A (1995) Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J Nucl Med 36: 1226-1231
33. Li X-M, Juorio AV, Paterson IA, Walz W, Zhu M-Y, Boulton AA (1992) Gene expression of aromatic L-amino acid decarboxylase in rat cultured glial cells. J Neurochem 59: 1172-1175
34. Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195: 453-464
35. Magnusson O, Mohringe B, Fowler CJ (1987) Comparison of the effects of dopamine D1 and D2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation. J Neural Transm 69: 163-177
36. Melamed E (1990) Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Parkinson's disease: anatomy, pathology, and therapy. Raven Press, New York, pp 61-66 (Adv Neurol 53)
37. Melamed E, Hefti F, Wurtman RJ (1980a) L-3, 4-Dihydroxyphenylalanine and L-5-hydroxytryptophan decarboxylase activities in rat striatum: effect of selective destruction of dopaminergic or serotonergic input. J Neurochem 34: 1753-1756
38. Melamed E, Hefti F, Wurtman RJ (1980b) Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 8: 558-563
39. Melamed E, Hefti F, Wurtman RJ (1980c) Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic neurons: the role of striatal capillaries. Brain Res 198: 244-248
40. Misu Y, Goshima Y, Ueda H, Okamura H (1996) Neurobiology of L-DOPAergic systems. Prog Neurobiol 49: 415-454
41. 11C]dopa. Brain Res 578: 122-128
42. Mouradian MM, Juncos JL, Fabbrini G, Chace TN (1987) Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 22: 475-479
43. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chace TN (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 24: 372-378
44. Mura A, Jackson D, Manley MS, Young SJ, Groves PM (1995) Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine. Brain Res 704: 51-60
45. Murata M, Kanazawa I (1993) Repeated L-DOPA administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat. Neurosci Res 16: 15-23
46. Nissbrandt H, Engberg G, Wilkstrom H, Magnusson T, Carlsson A (1988) NSD 1034: an amino acid decarboxylase inhibitor with a stimulatory action on dopamine synthesis not mediated by classical dopamine receptors. Naunyn Schmiedebergs Arch Pharmacol 338: 148-161
47. Onali P, Mereu G, Olianas MC, Bunse B, Rossetti Z, Gessa GL (1985) SCH 23390, a selective D1 dopamine receptor blocker, enhances the firing rate of nigral dopaminergic neurons but fails to activate striatal tyrosine hydroxylase. Brain Res 340: 1-7
48. Orosz D, Bennet JP (1992) Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat. Exp Neurol 115: 388-393
49. 3H] dopamine turn-over in striatum and frontal cortex in vivo linked to glutamate receptor antagonism. J Neurochem 70: 1979-1985
50. Robertson GS, Robertson HA (1989) Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 9: 3326-3331
51. Rossetti Z, Krajnc D, Neff NH, Hadjiconstantinou M (1989) Modulation of retinal aromatic L-amino acid decarboxylase via alpha 2 adrenoceptors. J Neurochem 52: 647-652
52. Rossetti ZL, Silvia CP, Krajnc D, Neff NH, Hadjiconstantinou M (1990) Aromatic L-amino acid decarboxylase is modulated by D1 dopamine receptors in rat retina. J Neurochem 54: 787-791
53. Skarsfeldt T (1988) Effect of chronic treatment with SCH 23390 and haloperidol on spontaneous activity of dopamine neurons in substantia nigra pars compacta (SNC) and ventral tegmental area (VTA) in rats. Eur J Pharmacol 145: 239-243
54. Soares-Da-Silva P, Garrett MC (1990) A kinetic study of the rate of formation of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the brain of the rat: implications for the origin of DOPAC. Neuropharmacol 29: 869-874
55. Touchet N, Bennet JP (1989) The metabolism of systemically-administered L-dihydroxyphenylalanine, by intact and dopamine-denervated striata, as revealed by brain microdialysis. Neuropharmacol 28: 1217-1222
56. Uitti RJ, Ahlskog JE (1996) A comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 5: 369-388
57. Wachtel SR, Abercrombie ED (1994) L-3, 4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63: 108-117
58. Westerink BH, Van Putten FM (1987) Simultaneous determination of the rates of synthesis and metabolism of dopamine in various areas of the rat brain: application to the effects of (+)-amphetamine. Eur J Pharmacol 133: 103-110
59. Xu JA, Hadjiconstantinou M, Neff NH (1985) Exposure to light accelerates the formation of dopamine from exogenous L-dopa in the rat retina. J Ocul Pharmacol 1: 177-181
60. Zhu M-Y, Juorio AV, Paterson IA, Boulton AA (1992) Regulation of aromatic L-amino acid decarboxylase by dopamine receptors in the rat brain. J Neurochem 58: 637-641
61. Zhu M-Y, Juorio AV, Paterson IA, Boulton AA (1993) Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopaminergic receptors. Eur J Pharmacol 238: 157-164